Abstracts

---

**2020**


- Hotte SJ, Winquist E, Chi KN, Ellard SL, Sridhar S, Emmenegger U, Salim M, Iqbal NN,


Olson D, Bao R, Allred JB, Strand C, Zha Y, Carll TC, Labadie B, Bastos BR, Butler MO,
Munster PN, Schwartz GK, Luke JJ. Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo). J Clin Oncol 37[Suppl; abstr 9505]. 2019.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


---

2018


- Renouf DJ, Dhani NC, Kavan P, Jonker DJ, Wei AC, Hsu T, Tang PA, Graham B, Gallinaro L, Hasan T, Li W, Hart K, Tu D, O’Callaghan CJ. The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D),


---


Bradbury P, Melosky B, Tu D, Nicholas G, Wheatley-Price P, Laurie S, Goss G,


structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial. J Clin Oncol 34[suppl; abstr 3621]. 2016.


2015

• Arts KE, Kato D, Dancey J. Establishment of a baseline to measure academic clinical trial activity in Canada. J Clin Oncol 33[suppl; abstr e17547].


randomized PORTEC-3 trial. J Clin Oncol 33[ suppl; abstr 5501].


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].


- Pennimtit MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[suppl 3; abstr 6]). 2015.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK,


2013


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)

Hematological Oncology 31[suppl 1], 96-150. 2013.


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.


- Fehringer G, Liu J, Pintilie M, Sykes J, Liu N, Cheng D, Chen Z, Seymour L, Der SD,


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liuw W, Sawyer M, Jefford M, Magoski NM, Haydon A, Walters I, Tu D, O’Callaghan CJ, on behalf of NCIC CTG and AGITG. Final Analysis of the Phase III randomized trial of cetuximab (CET) + either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


---

2011


- Chi KN, Eigl BJ, North S, Squire J, Eisenhauer E. A Phase II Study of SB939 in Patients

• Cuffe S, Graziano S, Bourredjem A, Pignon J-P, Ezzalfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Janne PA, Tsao MN, Shepherd FA. A pooled exploratory analysis of the impact of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC). J Thoracic Oncol 6[Suppl 2, abstr O42.01], S462, 2011.


• Goodwin RA, Jamal R, Tu D, Oza AM, Elit L. Predictors of Response and Progression to Temsirolimus in Women with Recurrent or Metastatic Endometrial Cancer. Canadian


Klotz L, O’Callaghan CJ, Ding K, Dearnaley DP, Higano CS, Horwitz EM, Malone S, Goldenberg SL, Gospodarowicz MK, Crook JM. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression...
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


of progression-free survival as a surrogate endpoint for overall survival when evaluating the effect of chemotherapy and radiotherapy in locally advanced lung cancer using data from four individual patient data meta-analyses. J Thoracic Oncol 6[6 suppl 2, abstr O42.05], S464, 2011.


2010

- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.
- Chia SK, Ung K, Bramwell VH, Tu D, Perou CM, Ellis MJ, Bernard PS, Vickery T, Shepherd LE, Nielsen TO. Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial. J Clin Oncol 28[15s,

• Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


• Jamal R, Goodwin RA, Tu D, Walsh W, Eisenhauer EA. Application of multinomial
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- **Phase II designs in trials of targeted agents.** OICR 3rd Annual Scientific Meeting, 2010.


- Trudeau ME, Clemons MJ, Dent RA, Kahn HJ, Parisi AM, Chapman JW, O’Brien P,


2009


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.
- Dancey JE. Testing for biomarker driven therapy (ERCC1 and EGFR). J Thoracic Oncol
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

4[9 suppl 1, abstr GR3.3]. S172-S173. 2009.


- Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.
S504-S505. 2009.


2008


- Bacon M. The evolving role of the nurse in clinical trials: Impact and opportunities.
Clinical Trials Seminar for Nurses (Tokyo), 2008.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


2007


- Cigler T, Yaffe MJ, Johnston D, Verma S, Findlay B, Wadden N, Pater JL, Richardson H, Tu D, Shangle Q, Goss PE. A placebo-controlled trial examining the effects of


• Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


2006

• Asmis TR, Ding K, Whitehead M, Seymour L, Shepherd FA, Winton T, Leighl N, Goss G.


- El-Maraghi RH, Ellard S, Gelmon K, McIntosh L, Seymour L. Pulmonary changes in a


MJ, Shepherd LE, Pritchard KL, He Z, Goss PE. The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Treatment and Research 100[Suppl 1], S23, 2006.


- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KL. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


• Eisenhauer EA. Combinations of agents for clinical development: which ones? How and when to develop these? Annals of Oncology 16[Suppl 3], 26, 2005.
• Gauthier I, Seymour L. Target effect and predictors of efficacy using laboratory correlative studies in early clinical trials: The Investigational New Drug Program at the NCIC Clinical Trials Group perspective. CIHR/NCIC National Meeting for Trainees, 2005.


• Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

• Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


• Maunsell E, Au H, Palmer M, Tu D, Whelan TJ, Goss PE, Davis A. Health-related quality of life in breast cancer survivors after 5 years of adjuvant tamoxifen. Quality of Life Research 14[9], 2092, 2005.

• Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.


Assouline S, Eisenhauer E. RECIST (Response Evaluation Criteria in Solid Tumors)


- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


- Fuchs C, Pollak M, Sargent DJ, Meyerhardt JA, Ramanathan RK, Williamson S, Findlay B, Green E, Goldberg RM. Insulin-like growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup


- Whelan T, Goss P, Ingle J, Pater J, Shepherd L, Palmer M, Tu D, Robert NJ, Martino S,


2003

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Kwok A, Zee B. Group sequential design for a global test statistic with mixed endpoints. Controlled Clin Trials 23(2S), 94s, 2002.


• Voskoglou-Nomikos T, Pater J, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft and mouse allograft pre-clinical cancer models.

• Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size, received dose-intensity and myelotoxicity of adjuvant chemotherapy in relation to outcome of premenopausal women with N1 breast cancer: results from a NCIC Clinical Trials Group randomized controlled trial. Breast Cancer Research and Treatment 69,


• Shepherd L, Parulekar W, Day A, Ottaway J, Bramwell V, Levine M, Pritchard K. Weight gain during adjuvant therapy in high risk pre/perimenopausal breast cancer patients:
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2000


Maroun J, Belanger K, Seymour L, Soulieres D, Charpentier D, Goel R, Stewart D,


- Shepherd FA, Arnold A, Neville A, Cormier Y, Davis M, Wierzbicki R, Dancey J,


1999


1998


Li T, Zee B, James K, Brundage M. Determination of toxicity health states for multiple myeloma patients - a comparison between correspondence analysis and clinicians’

- Moore M, Tannock I, Winquist E, Tolcher A, Bennett K, Seymour L. Gemcitabine and cisplatin is an active regimen for advanced transitional cell carcinoma.


1997


- Cripps C, Burnell M, Jolivet J, Lofters C, Fisher B, Panasci L, Iglesias J, Eisenhauer E. Phase II study of multi-targeted antifolate (LY231514) as first line therapy in patients...


Dent S, Zee B, Dancey J, Melnychuck D, Eisenhauer E, Steward W, Lu F. Design of


- Piccart M. Is TP the standard in first-line treatment? The EORTC experience.
Gynecologic Conference, 1996.

- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.

1995

- Eisenhauer E, Vermorken J, Myles J, van Glabbeke M. Tumour bulk, histology, and baseline hemoglobin may influence response in platinum pretreated ovarian cancer.


- Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


- Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


Bacon M. Impact and opportunities of clinical trials for cancer nursing. Canadian
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J. Health-related quality-of-life domains are affected by chemotherapy and extent of disease in patients with lung,


1993


- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.


• Zee B, Pater J, Torri V, Marsoni S, Pancera G, Milan C, Pignon J. Salvaging clinical
trials forced to terminate early by results of external information. Controlled Clin.Trials
• Zee B, Pater J, Torri V, Marsoni S, Pancera G, Milan C, Pignon J. Salvaging trials forced
to terminate early by external results and a design of pooled-international-trials. Clinical
Trials in Oncology, 1993.
• Zee B, Pho L, Koski B. System for monitoring timing of data review and entry. Controlled
• Zee B. Growth curve model for quality of life data with missing and informative right

1992

• Ciampi A, Zee B, Hendricks L, Pater J. Correcting for confounding in survival analysis:
• Connors J, Klimo P, Adams G, Burns B, Cooper I, Meyer R, O'Reilly S, Pater J, Quirt I,
hybrid versus alternating MOPP/ABVD for advanced Hodgkin's disease.
• Coppin C, Gospodarowicz M, Dixon P, Tannock I, Zee B, Sullivan L. Improved local
control of invasive bladder cancer by concurrent cisplatin and preoperative or radical
• Cormier Y, Eisenhauer E, Gregg R, Stewart D, Muldal A. Gemcitabine is active in
patients with previously untreated extensive small cell lung cancer. A phase II study.
• Desjardins C, Pater J, Zee B, Torri W, Marsoni S, Colombo N, Bonazzi C. Prognostic
factors after a negative second-look laparotomy in ovarian cancer: a Canada-Italy study.
Ann.Oncol. 3(Suppl.5), 107, 1992.
M, Gregory W. Application to ovarian cancer of a mathematical model relating response
• Eisenhauer E, Ten Bokkel-Huinink W, Swenerton K, Mangioni C, van der Burg M, Kerr I,
European-Canadian trial of high vs low dose and short vs long infusion in ovarian cancer
coordinated by the NCI Canada Clinical Trials Group. NCI Workshop on Taxol and
• Eisenhauer E, Cormier Y, Gregg R, Stewart D, Muldal A. Gemcitabine is active in
patients with previously untreated extensive small cell lung cancer. A phase II study of
• Eisenhauer E, Belanger K, Erlichman C, Gregg R, Shore T, Dallaire B, Gyves J, Grillo-
Lopez A. DUP 937: a new anthrapyrazole in clinical trials. NCI-EORTC Symposium on
New Drugs in Cancer Therapy, 1992.
• Grever M, Kopecky K, Head D, Cassileth P, Golomb H, Habermann T, Rai K,
Eisenhauer E, Cheson B. A randomized comparison of deoxycoformycin versus
alpha-2a interferon in previously untreated patients with hairy cell leukemia. An NCI-
sponsored intergroup study (SWOG, ECOG, CALGB, NCIC CTG).


- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


1991


1989


Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


1988


1987

- Eisenhauer E, Pritchard K, Perrault D, Verma S, Pater J. Phase II study of intravenous


1986


- Pater J, Elliott C. The effect of different measures of outcome on the results of studies of

- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985


1984

Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


1983


1981

- Belch A, Ronald AR, Feld R, Pater J. Efficacy of lithium during remission induction of